Cytokinetics, Incorporated (CYTK)
Pre-market:
| Previous close | 46.72 |
| Open | 46.69 |
| Bid | 0.00 x 900 |
| Ask | 54.00 x 1200 |
| Day's range | 45.14 - 52.69 |
| 52-week range | 29.10 - 52.69 |
| Volume | |
| Avg. volume | 1,359,819 |
| Market cap | 4.438B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.21 |
| Earnings date | 01 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 62.75 |
- Zacks
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cytokinetics Reports Second Quarter 2022 Financial Results
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quar
- GlobeNewswire
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
New Data Span Ten Years of Clinical Trial Research from Nearly 600 People with ALSSOUTH SAN FRANCISCO, Calif., AND WASHINGTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from Cytokinetics’ completed clinical trials in ALS including, BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improve
